Pfizer breast cancer drug gets breakthrough label

by The Associated Press

Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.

Pfizer shares jumped nearly 3 percent following the news.

The breakthrough designation is meant to speed up development and review of experimental treatments seen as big advances.

The drug, palbociclib (pal-boh-SEYE'-clib), is being evaluated as an initial treatment for a subgroup that includes about 60 percent of postmenopausal women whose breast cancer is locally advanced or has spread elsewhere in the body. Their tumors are fueled by the .

Pfizer is currently running a late-stage study of palbociclib, comparing its effects in combination with letrozole with the effects of letrozole alone. Letrozole, sold under the brand Femara, blocks production of estrogen.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Afinitor approved for advanced breast cancer

Jul 23, 2012

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food ...

New drug regimens may slow advanced breast cancer

Dec 05, 2012

(HealthDay)—An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies ...

Recommended for you

Enzyme controlling metastasis of breast cancer identified

6 minutes ago

Researchers at the University of California, San Diego School of Medicine have identified an enzyme that controls the spread of breast cancer. The findings, reported in the current issue of PNAS, offer hope f ...

User comments